Cargando…

A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins

We have created a novel fluorescent model of a human ovarian carcinoma xenograft overexpressing receptor HER2, a promising molecular target of solid tumors. The model is based on a newly generated SKOV-kat cell line stably expressing far-red fluorescent protein Katushka. Katushka is most suitable fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zdobnova, Tatiana, Sokolova, Evgeniya, Stremovskiy, Oleg, Karpenko, Dmitry, Telford, William, Turchin, Ilya, Balalaeva, Irina, Deyev, Sergey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741577/ https://www.ncbi.nlm.nih.gov/pubmed/26436696

Ejemplares similares

Recombinant Immunotoxin 4D5scFv-PE40 for Targeted Therapy of HER2-Positive Tumors
por: Sokolova, E. A., et al.
Publicado: (2015)

Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro
por: Balalaeva, I. V., et al.
Publicado: (2017)

HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis
por: Sokolova, Evgeniya, et al.
Publicado: (2017)

HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model
por: Sokolova, Evgeniya A., et al.
Publicado: (2019)

Self-Assembling Complexes of Quantum Dots and scFv Antibodies for Cancer Cell Targeting and Imaging
por: Zdobnova, Tatiana A., et al.
Publicado: (2012)

The Effect of the Targeted Recombinant Toxin DARPin-PE40 on the Dynamics of HER2-Positive Tumor Growth
por: Sokolova, E.A., et al.
Publicado: (2017)

Penetration Efficiency of Antitumor Agents in Ovarian Cancer Spheroids: The Case of Recombinant Targeted Toxin DARPin-LoPE and the Chemotherapy Drug, Doxorubicin
por: Sokolova, Evgeniya, et al.
Publicado: (2019)

Expression of anti-tumor recombinant IgG- and IgE-like genes in eukaryotic cells
por: Polanovsky, O. L., et al.
Publicado: (2008)

Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
por: Bera, Tapan K.
Publicado: (2020)

Far-Red Fluorescent Murine Glioma Model for Accurate Assessment of Brain Tumor Progression
por: Mishchenko, Tatiana A., et al.
Publicado: (2022)

Recombinant immunotoxins development for HER2-based targeted cancer therapies
por: Mahmoudi, Reza, et al.
Publicado: (2021)

A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
por: Kollmorgen, Gwendlyn, et al.
Publicado: (2017)

Quantum Dots for Molecular Diagnostics of Tumors
por: Zdobnova, T.A., et al.
Publicado: (2011)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Targeted Delivery to Tumors: Multidirectional Strategies to Improve Treatment Efficiency
por: Kutova, Olga M., et al.
Publicado: (2019)

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
por: Leshem, Yasmin, et al.
Publicado: (2019)

Preclinical Studies of Granulysin-Based Anti-MUC1-Tn Immunotoxins as a New Antitumoral Treatment
por: Guerrero-Ochoa, Patricia, et al.
Publicado: (2022)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
por: Paquette, Michel, et al.
Publicado: (2020)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

The phytochrome red/far-red photoreceptor superfamily
por: Sharrock, Robert A
Publicado: (2008)

Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts
por: Tomé-Amat, Jaime, et al.
Publicado: (2015)

Protonation of the Biliverdin IXα Chromophore in the Red and Far-Red Photoactive States of a Bacteriophytochrome
por: Modi, Vaibhav, et al.
Publicado: (2019)

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model
por: Xu, Tianqi, et al.
Publicado: (2023)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

Construction of an immunotoxin via site-specific conjugation of anti-Her2 IgG and engineered Pseudomonas exotoxin A
por: Lee, Byeong Sung, et al.
Publicado: (2019)

Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
por: Peng, Yanjie, et al.
Publicado: (2023)

Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
por: Flavell, D. J., et al.
Publicado: (1995)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

A novel Carcinoembryonic Antigen (CEA)-Targeted Trimeric Immunotoxin shows significantly enhanced Antitumor Activity in Human Colorectal Cancer Xenografts
por: Lázaro-Gorines, R., et al.
Publicado: (2019)

Patient-derived xenografts as preclinical neuroblastoma models
por: Braekeveldt, Noémie, et al.
Publicado: (2017)

Genetically Encoded Immunophotosensitizer 4D5scFv-miniSOG is a Highly Selective Agent for Targeted Photokilling of Tumor Cells In Vitro
por: Mironova, Kristina E., et al.
Publicado: (2013)

Data on characterization of magnetic nanoparticles stabilized with fusion protein of Barstar and C-term part of Mms6
por: Shipunova, Victoria O., et al.
Publicado: (2018)

Systemic immunotoxin therapy of cancer: advances and prospects.
por: Wawrzynczak, E. J.
Publicado: (1991)

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary
por: Tortorella, Lori L., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5270m1965i2f7i2ktrbdqjkl6n